JFG
SNDX icon

Jefferies Financial Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Jefferies Financial Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-413
Closed -$8.68K – 2171
2025
Q4 		$8.68K Sell
413
-8,587
-95% -$150K ﹤0.01% 1818
2025
Q3 		$138K Sell
9,000
-14,000
-61% -$183K ﹤0.01% 1314
2025
Q2 		$215K Buy
+23,000
New +$253K ﹤0.01% 1107

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Jefferies Financial Group's SNDX Position: Q1 2026 in Review

Jefferies Financial Group sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 413 shares — an estimated $8.68K sold.

Jefferies Financial Group first reported a position in SNDX in Q2 2025 and held it in 3 quarters. The position peaked at $215K in Q2 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Jefferies Financial Group reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 413 Syndax Pharmaceuticals shares in Q1 2026, an estimated $8.68K.
  • Jefferies Financial Group first reported a position in Syndax Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Jefferies Financial Group's Syndax Pharmaceuticals position peaked at $215K in Q2 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.